John G. Houston, Ph.D.   |   Director

Dr. Houston is President and Chief Executive Officer of, and serves on the board of directors of, Arvinas, Inc. He also currently serves on the boards of directors of Oerth Bio, Cybrexa Therapeutics and BioCT. Prior to Arvinas, he spent more than 18 years at Bristol Myers Squibb (BMS) in roles of increasing responsibility and had accountability for all Discovery Biology disease teams, as well as various Discovery technology departments. He was the senior vice president of Specialty Discovery and R&D Site Development at BMS and previously worked in various roles across BMS’s Discovery Biology, Applied Biotechnology and Early Discovery Chemistry departments. Dr. Houston was a member of the BMS senior executive leadership team, which reviewed and approved over 200 pre-clinical candidates for progression into early development, several of which advanced into late-stage clinical trials, and toward commercialization. He was also the principal architect and driver of the ‘Leveraging Technology’ initiative at BMS, which led to an industry-leading integrated lead discovery and optimization process. Prior to joining BMS, he worked at Glaxo Welcome Research and Development in the UK, where he served as head of the Lead Discovery Unit. Dr. Houston obtained a B.Sc. in Medical Microbiology from Glasgow University and a Ph.D. in Microbial Biochemistry from Heriot-Watt University, Edinburgh.  Dr. Houston joined NextCure’s board of directors in September 2020.

• David Kabakoff, Ph.D. Chairman • Michael Richman Director • Elaine V. Jones, Ph.D. Director • Chau Q. Khuong Director • John G. Houston, Ph.D. Director • Stephen Webster Director • Ellen G. Feigal, M.D. Director • Anne Borgman, M.D. Director